Minerva Neurosciences, Inc (NERV): Price and Financial Metrics


Minerva Neurosciences, Inc (NERV): $0.43

0.04 (+10.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NERV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NERV Stock Price Chart Interactive Chart >

Price chart for NERV

NERV Price/Volume Stats

Current price $0.43 52-week high $3.14
Prev. close $0.39 52-week low $0.33
Day low $0.41 Volume 73,900
Day high $0.43 Avg. volume 111,430
50-day MA $0.62 Dividend yield N/A
200-day MA $1.04 Market Cap 18.37M

Minerva Neurosciences, Inc (NERV) Company Bio


Minerva Neurosciences, Inc. focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company was founded in 2007 and is based in Waltham, Massachusetts.


NERV Latest News Stream


Event/Time News Detail
Loading, please wait...

NERV Latest Social Stream


Loading social stream, please wait...

View Full NERV Social Stream

Latest NERV News From Around the Web

Below are the latest news stories about Minerva Neurosciences Inc that investors may wish to consider to help them evaluate NERV as an investment opportunity.

Insider Selling: Minerva Neurosciences, Inc. (NASDAQ:NERV) Director Sells 55,635 Shares of Stock

Minerva Neurosciences, Inc. (NASDAQ:NERV) Director David Kupfer sold 55,635 shares of the stock in a transaction dated Wednesday, December 1st. The shares were sold at an average price of $0.88, for a total transaction of $48,958.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through []

Transcript Daily | December 6, 2021

Minerva Neurosciences (NASDAQ:NERV) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a report released on Friday morning, Zacks.com reports. They currently have $1.00 target price on the biopharmaceutical companys stock. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and []

Dakota Financial News | December 6, 2021

Minerva Neurosciences (NASDAQ:NERV) Stock Rating Upgraded by Zacks Investment Research

Minerva Neurosciences (NASDAQ:NERV) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Friday, Zacks.com reports. The brokerage currently has a $1.00 target price on the biopharmaceutical companys stock. Zacks Investment Researchs price objective indicates a potential upside of 7.99% from the companys current []

Transcript Daily | December 5, 2021

Minerva Neurosciences (NASDAQ:NERV) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central []

Dakota Financial News | December 5, 2021

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 1, 2021

Read More 'NERV' Stories Here

NERV Price Returns

1-mo -21.12%
3-mo -36.95%
6-mo -57.00%
1-year -85.42%
3-year -91.75%
5-year -94.82%
YTD -46.32%
2021 -65.77%
2020 -67.09%
2019 5.49%
2018 11.40%
2017 -48.51%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7199 seconds.